Nanogroup

Nanogroup OCF Margin

The Operating Cash Flow Margin of Nanogroup (NNG.WA) as of Nov 5, 2026 is -272,205.71 %. In the previous year, Operating Cash Flow Margin was -235,810.55 % — a change of 15.43% (lower).

OCF Margin

-272,205.71 %

YoY

15.43%

Last updated:

Operating Cash Flow Margin of Nanogroup is 2024 -272,205.71 % . Operating Cash Flow Margin of Nanogroup was 2023 -235,810.55 % . It decreases by 15.43% lower compared to the previous year.

The Nanogroup OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-6,367.15 PLN
Jan 1, 2018
-3,149.06 PLN
Jan 1, 2019
-448.21 PLN
Jan 1, 2020
-195.98 PLN
Jan 1, 2021
-649.58 PLN
Jan 1, 2022
-2,640.59 PLN
Jan 1, 2023
-235,810.55 PLN
Jan 1, 2024
-272,205.71 PLN
The Nanogroup OCF Margin history
YEAROCF MarginYoY
-272,205.71 %+15.43%
-235,810.55 %+8,830.23%
-2,640.59 %+306.51%
-649.58 %+231.46%
-195.98 %-56.28%
-448.21 %-85.77%
-3,149.06 %-50.54%
-6,367.15 %+273.78%
-1,703.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanogroup Stock analysis

What does Nanogroup do? NanoGroup SA generates revenue through its advanced biotechnological projects focused on cancer prevention, early diagnosis, and targeted therapies. The company's portfolio includes NanoVelos, which develops drug delivery systems for oncologic medicines, and NanoSanguis, which creates artificial blood for accident victims and an organ preservation system called Organ farm. NanoThea specializes in early cancer detection technology. These products are sold to medical institutions, research facilities, and healthcare providers seeking innovative solutions in oncology and organ preservation. The firm's revenue streams come from licensing agreements and direct sales of its biotechnological solutions. NanoVelos targets pharmaceutical companies needing optimized drug delivery, while NanoSanguis serves emergency medical services and trauma centers requiring artificial blood and organ preservation. NanoThea's early cancer detection systems are purchased by diagnostic centers and hospitals aiming to improve patient outcomes through early intervention. NanoGroup SA's business model relies on the commercialization of its R&D projects, with each brand addressing specific medical needs. The company's focus on cancer-related technologies and organ preservation positions it as a key supplier in the biotech sector, serving healthcare providers and research organizations that require cutting-edge medical solutions. Nanogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanogroup stock

Operating Cash Flow Margin of Nanogroup is -272,205.71 % in 2024.

Operating Cash Flow Margin of Nanogroup changed from -235,810.55 % to -272,205.71 %, representing a 15.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Nanogroup since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Nanogroup with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nanogroup

All Key Metrics — Nanogroup